•A recent phase Ib study of reformulated niclosamide with abiraterone and prednisone in patients with advanced prostate cancer showed a promising preliminary efficacy signal with low toxicity.
•Niclosamide is one the first AR-V7 inhibitors to be tested in clinical trials.
•Preclinical findings suggest that AR-V7 inhibition alone cannot explain the magnitude of antitumor effects of niclosamide, either used alone or in combination with abiraterone or enzalutamide.
•Niclosamide, a well known mitochondrial uncoupler, has pleiotropic effects.
•The mechanism of action of reformulated niclosamide in patients with CRPC needs to be further investigated. This will potentially lead to new opportunities to develop and investigate even more selective and effective treatments against prostate cancer.
Written by
Graham49
To view profiles and participate in discussions please or .
People should remember that regular niclosamide does not work. The only way to get the modified niclosamide (better GI absorption) is in a clinical trial.
But neither that article nor their Phase 1+2 clinical trials give a hint about what modifications they applied to the original Niclosamide.
From what I read, the original Niclosamide has a poor bioavailability and therefore probably can't establish a sufficient serum concentration to prevent Abiraterone acetate (Zytiga) resistance. (my prostate cancer cells became resistant after 10 months).
I think it would be interesting if somebody would initiate a clinical trial using Abiraterone acetate plus CP-COV03 (a modified Niclosamide) developed by the Korean company 'Hyundai Bioscience'. According to this article they greatly improved its bioavailability:
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
AR-V7 - CTC's - Risk of Death
AR-V7 testing
